Answers are grounded in this paper and cite their sources.
Induced pluripotent stem cells (iPSCs) offer a promising platform to model early embryonic developmental processes, to create disease models that can be evaluated by drug screens as well as proof-of-concept experiments for regenerative medicine. However, generation of iPSC-derived hemato-endothelial and hematopoietic progenitor cells for these applications is challenging due to variable and limited cell numbers, which necessitates enormous up-scaling or development of demanding protocols. Here, we unravel the function of key transcriptional regulators SCL , LMO2 , GATA2 , and ETV2 (SLGE) on early hemato-endothelial specification and establish a fully inducible and stepwise hemato-endothelial forward programming system based on SLGE-regulated overexpression. Regulated induction of SLGE in stable SLGE-iPSC lines drives very efficient generation of large numbers of hemato-endothelial progenitor cells (CD144 + /CD73 – ), which produce hematopoietic progenitor cells (CD45 + /CD34 + /CD38 – /CD45RA − /CD90 + /CD49f + ) through a gradual process of endothelial-to-hematopoietic transition (EHT).
No takes yet. Share an insight, caveat, or question.
Lange et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: